Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dyckman

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 2, 2014
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseasesQing Shi, Andrew Tebben, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
5-amino-pyrazoles as potent and selective p38α inhibitorsJagabandhu Das, Robert V Moquin, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|April 2, 2014
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseasesQing Shi, Andrew Tebben, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
5-amino-pyrazoles as potent and selective p38α inhibitorsJagabandhu Das, Robert V Moquin, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Pageof 6